Vixticibart Biosimilar Monoclonal Antibody (NPR1) for Research

Cat No.: GMP-Bios-INN-1462

Anti-NPR1/ANPRA/ANPa/GUC2A/GUCY2A/NPRA therapeutic antibody (Pre-made Vixticibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Vixticibart (development code REGN-5381) is a human monoclonal antibody that acts as an allosteric agonist of natriuretic peptide receptor 1 (NPR1). It is developed by Regeneron Pharmaceuticals for heart failure and uncontrolled hypertension. Further development details are under investigation.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1462-1mg 1mg 3090
GMP-Bios-INN-1462-10mg 10mg
GMP-Bios-INN-1462-100mg 100mg
GMP-Bios-INN-1462-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Vixticibart biosimilar, Whole mAb, Anti-NPR1/ANPRA/ANPa/GUC2A/GUCY2A/NPRA Antibody: Anti-NPR1/Atrial natriuretic peptide receptor 1/Atrial natriuretic peptide receptor type A (ANP-A/ANPR-A therapeutic antibody
INN Name Vixticibart
Target NPR1/ANPRA/ANPa/GUC2A/GUCY2A/NPRA
Format Whole mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G4
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status Active
100% SI Structure 8tga:EF:HL/8tg9:HL:EF
99% SI Structure None
95-98% SI Structure None
Year Proposed 2024
Year Recommended 2024
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech na